Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EffRx Pharmaceuticals SA

www.effrx.com

Latest From Vicept Therapeutics Inc.

Galderma’s Mirvaso Joins Rosacea Market With Indication For Facial Erythema

The dermatology company is able to offer a continuum of care for patients with the skin condition now that it has received FDA approval for a third product to treat the condition. The latest offering treats the most mild form of the condition.

BioPharmaceutical North America

Actelion, Under Pressure To Diversify, Eyes Rare Disease Start-Up Ceptaris

Actelion is paying a $25 million upfront for an option to acquire Ceptaris Therapeutics, contingent upon the latter’s receiving FDA approval for its only asset, Valchlor, which faces an August PDUFA date. If the deal closes, Ceptaris will receive another $225 million plus milestones from the Swiss-based biotech.

BioPharmaceutical Deals

Financings Of The Fortnight: Could California’s Regenerative Medicine Ballot Initiative Pass Today?

Plus news on recent financings by bluebird bio, Puma Biotechnology, Atara Biotherapeutics and Aclaris Therapeutics.

BioPharmaceutical Business Strategies

Vicept Management, VCs Team Up Again To Launch Aclaris With $21M

Newly launched dermatology start-up Aclaris brings the band back together, as Vicept’s core management and VCs begin a new endeavor in a sometimes-neglected sector.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • EffRx Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • EffRx Pharmaceuticals SA
  • Senior Management
  • Lorenzo Bosisio, CEO
    Paolo Agnoluzzi, Interim CFO
    Timo Schmidt, PhD, CSO
  • Contact Info
  • EffRx Pharmaceuticals SA
    Phone: 44 503 78 60
    Wolleraustrasse 41B
    Freienbach, FL 8807
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register